UPDATE 1-European Commission clears Amarin's fish-oil derived heart drug Vazkepa [Reuters]
Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share (AMRN)
Last amarin corporation plc - american depositary shares, each representing one ordinary share earnings: 4/30 05:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.amarincorp.com/investors
Company Research
Source: Reuters
UPDATE 1-European Commission clears Amarin's fish-oil derived heart drug Vazkepa By Reuters Staff 2 Min Read (Adds CEO quote, details of Europe approval and drug, background on U.S. approval) March 30 (Reuters) - Amarin Corporation Plc said on Tuesday that the European Commission has granted its fish-oil derived heart drug Vazkepa a marketing authorization in the European Union. The authorization allows Amarin to market Vazkepa, which is sold in the United States as Vascepa, as a treatment to help reduce strokes, heart attacks and other major cardiovascular events in high-risk patients across Europe, the company said. Vazkepa, a highly purified form of omega-3 fatty acid, won U.S. approval in 2012 to lower high triglycerides - a type of blood fat that can increase the risk of heart disease. In December 2019, U.S. health regulators approved here expanding the drug's label to include its heart benefit claims, opening a multibillion-dollar market opportunity for the company. The Europea
Show less
Read more
Impact Snapshot
Event Time:
AMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMRN alerts
High impacting Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share news events
Weekly update
A roundup of the hottest topics
AMRN
News
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024GlobeNewswire
- Metastatic Liver Cancer Pipeline Insight 2024, Featuring Key Players Oncorus, Sirnaomics, Codiak BioSciences, RemeGen, Amarin, Medivir, AstraZeneca, Amal Therapeutics and Boehringer Ingelheim [Yahoo! Finance]Yahoo! Finance
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24GlobeNewswire
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups [Yahoo! Finance]Yahoo! Finance
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsGlobeNewswire
AMRN
Earnings
- 2/29/24 - Beat
AMRN
Sec Filings
- 4/19/24 - Form 4
- 4/19/24 - Form 4
- 4/19/24 - Form 4
- AMRN's page on the SEC website